Historic: Brazil Approves World's First Single-Dose Dengue Vaccine

Written By :  Anshika Mishra
Published On 2025-11-27 12:15 GMT   |   Update On 2025-11-27 12:15 GMT
Advertisement

Brazil has approved the world’s first single-dose dengue vaccine, marking a historic milestone as dengue cases rise globally amid climate change. The vaccination, known as Butantan-DV, was developed by the Butantan Institute in São Paulo and authorized by Brazil’s health regulatory agency ANVISA for people aged 12 to 59. Unlike the current vaccine TAK-003, which requires two doses three months apart, Butantan-DV’s single dose allows for quicker, easier vaccination efforts.

Advertisement

After eight years of clinical trials involving over 16,000 volunteers, the vaccine showed 91.6% efficacy against severe dengue. Dengue, spread by Aedes mosquitoes and known as “breakbone fever,” caused a record 14.6 million cases worldwide in 2024, with half of the deaths occurring in Brazil. The country has partnered with Chinese company WuXi Biologics to secure around 30 million doses for delivery in late 2026, aiming to combat the disease’s growing threat driven by global warming, reports Folha De S.Paulo.

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News